HONG KONG –MSD China Holding Co. Ltd. (known as Merck & Co. Inc. in the U.S. and Canada) received approval for Keytruda (pembrolizumab) in China, making it the second PD-1 inhibitor drug approved in the country after Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and the first one for advanced melanoma. Read More
HONG KONG – Sinovant Sciences Ltd., of Shanghai, has joined hands with U.S. firm Renexxion LLC to develop naronapride, an investigational gastrointestinal prokinetic for treating irritable bowel syndrome with constipation (IBS-C). Read More
HONG KONG – Japan's Sanbio Co. Ltd., a maker of regenerative medicines for neurological disorders, is working with Keio University School of Medicine to research its SB-623 drug for the treatment of dementia, including Alzheimer's disease and cerebral vascular dementia. Read More
HONG KONG – Shanghai Green Valley (Group) Co. Ltd. is gearing up to file for approval in China later this year after its sodium oligomannurarate (GV-971) capsules significantly improved cognition among patients with mild to moderate Alzheimer's disease (AD) in phase III trials. Read More
HONG KONG – Chinese biopharmaceutical firm Beigene Ltd. filed with the Hong Kong Stock Exchange (HKEX) for a monster IPO that could raise more than $1 billion. It is the second biotech firm to seek an HKEX listing after Hangzhou-based Ascletis Pharma Inc. priced a nearly $400 million offering earlier this month. Read More
I-Mab Biopharma, of Shanghai, and South Korean-based ABL Bio Corp. said they entered a strategic partnering agreement where ABL Bio will in-license the global rights, excluding greater China, to I-Mab's bispecific antibodies (BsAb) of undisclosed target with licensing payments of approximately $100 million in total. Read More
